Asset Details
Do you wish to reserve the book?
Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model
Do you wish to request the book?
Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model
2024
Overview
Purpose
Invasive candidiasis poses a life-threatening risk, and early prognosis assessment is vital for timely interventions to reduce mortality. Serum C5a levels have recently been linked to prognosis, but confirmation in cancer patients is pending.
Methods
We detected the concentrations of serum C5a in hospitalized cancer patients with invasive candidiasis from 2020 to 2023, and retrospectively analyzed the clinical data.
Results
372 cases were included in this study, with a 90-day mortality rate of 21.8%.
Candida albicans
(48.7%) remained the predominant pathogen, followed by
Candida glabrata
(25.5%),
Candida tropicalis
(12.4%), and
Candida parapsilosis
(8.3%). Gastrointestinal cancer was the most diagnosed pathology type (37.6%). Serum C5a demonstrated a noteworthy correlation with 90-day mortality, and employing a cutoff value of 36.7 ng/ml revealed significantly higher 90-day mortality in low-C5a patients (41.2%) compared to high-C5a patients (6.3%) (
p
< 0.001). We also identified no source control, no surgery, metastasis, or chronic renal failure independently correlated with the 90-day mortality. Based on this, a prognostic model combining C5a and clinical parameters was constructed, which performed better than models built solely on C5a or clinical parameters. Furthermore, we weighted scores to each parameter in the model and presented diagnostic sensitivity and specificity corresponding to different score points calculated by the model.
Conclusion
We constructed a prognostic scoring model including serum C5a and clinical parameters, which would contribute to precise prognosis assessment and benefit the outcome among cancer patients.
